Patents by Inventor Howard M. Goodman

Howard M. Goodman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6841722
    Abstract: Disclosed is a Arabidopsis sse1 gene, which is responsible for protein and oil body biogenesis. The invention further provides methods for using the disclosed gene for modifying the components of plant storage reserve materials.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: January 11, 2005
    Assignee: The General Hospital Corporation
    Inventors: Yun Lin, Lin Sun, Long V. Nguyen, Howard M. Goodman
  • Patent number: 6355411
    Abstract: Disclosed are bacterial virulence polypeptides and nucleic acid sequences (e.g., DNA) encoding such polypeptides, and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing such polypeptides to screen for antibacterial or bacteriostatic compounds.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: March 12, 2002
    Assignee: The General Hospital Corporation
    Inventors: Frederick Ausubel, Howard M. Goodman, Laurence G. Rahme, Shalina Mahajan-Miklos, Man-Wah Tan, Hui Cao, Eliana Drenkard, John Tsongalis
  • Patent number: 6248937
    Abstract: Identification, cloning and sequencing of the Arabidopsis ABI4 gene involved in seed response to abscisic acid (ABA) that regulates production of seed nutrient reserves and desiccation protectants. A method for regulating seed development, viability, stress-tolerance and nutrient reserves.
    Type: Grant
    Filed: April 27, 1999
    Date of Patent: June 19, 2001
    Assignee: The Regents of the University of California
    Inventors: Ruth R. Finkelstein, Tim Lynch, Howard M. Goodman, Ming-Li Wang
  • Patent number: 6071730
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 6, 2000
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
  • Patent number: 6015794
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 18, 2000
    Assignee: The General Hospital Corporation
    Inventors: James Haseloff, Howard M. Goodman
  • Patent number: 6013472
    Abstract: The invention relates to the DNA and protein encoded by the GA4 locus. This protein is believed to be a member of the family of enzymes involved in the biosynthesis of the gibberellin family (GA) of plant growth hormones which promote various growth and developmental processes in higher plants, such as seed germination, stem elongation, flowering and fruiting. More specifically, the protein encoded by the GA4 locus is an hydroxylase. The invention also relates to vectors containing the DNA and the expression of the protein encoded by the DNA of the invention in a host cell. Additional aspects of the invention are drawn to host cells transformed with the DNA or antisense sequence of the invention, the use of such host cells for the maintenance, or expression or inhibition of expression of the DNA of the invention and to transgenic plants containing DNA of the invention. Finally, the invention also relates to the use of the protein encoded by the GA4 locus to alter aspects of plant growth.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: January 11, 2000
    Assignee: The General Hospital Corporation
    Inventors: Hui-Hwa Chiang, Howard M. Goodman
  • Patent number: 6010904
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 4, 2000
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
  • Patent number: 5925807
    Abstract: The invention relates to the DNA and protein encoded by the GA4 locus. This protein is believed to be a member of the family of enzymes involved in the biosynthesis of the gibberellin family (GA) of plant growth hormones which promote various growth and developmental processes in higher plants, such as seed germination, stem elongation, flowering and fruiting. More specifically, the protein encoded by the GA4 locus is an hydroxylase. The invention also relates to vectors containing the DNA and the expression of the protein encoded by the DNA of the invention in a host cell. Additional aspects of the invention are drawn to host cells transformed with the DNA or antisense sequence of the invention, the use of such host cells for the maintenance, or expression or inhibition of expression of the DNA of the invention and to transgenic plants containing DNA of the invention. Finally, the invention also relates to the use of the protein encoded by the GA4 locus to alter aspects of plant growth.
    Type: Grant
    Filed: March 25, 1997
    Date of Patent: July 20, 1999
    Assignee: General Hospital Corporation
    Inventors: Hui-Hwa Chiang, Howard M. Goodman
  • Patent number: 5882907
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 16, 1999
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
  • Patent number: 5874414
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: November 17, 1993
    Date of Patent: February 23, 1999
    Assignee: The General Hospital Corporation
    Inventors: James Haseloff, Howard M. Goodman
  • Patent number: 5866384
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 2, 1999
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
  • Patent number: 5866779
    Abstract: The present invention concerns the cloning and sequencing of DNA corresponding to the GA1 locus of A. thaliana which encodes ent-kaurene synthetase, to vectors containing said DNA, to vectors capable of expressing said DNA, and to hosts transformed with said vectors. The invention further concerns the use of the GA1 gene, and regulatory regions thereof, in the generation of chimeric and transgenic plants.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: February 2, 1999
    Assignee: The General Hospital Corporation
    Inventors: Tai-Ping Sun, Howard M. Goodman, Frederick M. Ausubel
  • Patent number: 5863774
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 26, 1999
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
  • Patent number: 5859346
    Abstract: Purified DNA encoding crucifer AFT proteins and chimeric transcriptional activator proteins from such DNA are disclosed. Such proteins are also involved in plant defense mechanisms by interacting with proteins involved in protecting plants from pathogens. The recombinant polypeptides and fragments are useful in methods of modulating plant gene expression.
    Type: Grant
    Filed: November 14, 1996
    Date of Patent: January 12, 1999
    Assignee: The General Hospital Corporation
    Inventors: Hong Zhang, Howard M. Goodman
  • Patent number: 5849548
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 15, 1998
    Assignees: The General Hospital Corporation, The President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
  • Patent number: 5641673
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are base a upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: December 23, 1993
    Date of Patent: June 24, 1997
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
  • Patent number: 5623054
    Abstract: Purified DNA encoding crucifer AFT proteins and chimeric transcriptional activator proteins from such DNA are disclosed. Such proteins are also involved in plant defense mechanisms by interacting with proteins involved in protecting plants from pathogens. The recombinant polypeptides and fragments are useful in methods of modulating plant gene expression.
    Type: Grant
    Filed: June 23, 1994
    Date of Patent: April 22, 1997
    Assignee: The General Hospital Corporation
    Inventors: Hong Zhang, Howard M. Goodman
  • Patent number: 5436139
    Abstract: The present invention is directed to an expression vector containing DNA which encodes recombinant full-length hepatitis B surface antigen protein wherein said vector is free of DNA encoding hepatitis B core antigen protein in a microorganism.
    Type: Grant
    Filed: July 8, 1993
    Date of Patent: July 25, 1995
    Assignee: The Regents of the University of California
    Inventors: William J. Rutter, Howard M. Goodman
  • Patent number: 5196194
    Abstract: Recombinant full-length Hepatitis B surface antigen protein is disclosed. This protein is useful in vaccines for the prevention of Hepatitis B infection.
    Type: Grant
    Filed: December 7, 1984
    Date of Patent: March 23, 1993
    Assignee: The Regents of the University of California
    Inventors: William J. Rutter, Howard M. Goodman
  • Patent number: 5145782
    Abstract: A DNA expression vector is described which is derived from the highly efficient trp operon. The expression vector provides for the direct expression of an inserted gene or cDNA. Using the expression vector described herein, it is possible to obtain the protein coded by the gene or cDNA directly and not as a fusion protein. The expression vector comprises the promoter, operator and leader ribosomal binding site of the trp operon.
    Type: Grant
    Filed: November 17, 1987
    Date of Patent: September 8, 1992
    Assignee: The Regents of the University of California
    Inventors: Robert A. Hallewell, Jeffrey C. Edman, William J. Rutter, Howard M. Goodman